STOCKHOLDERS' EQUITY	9 Months Ended
Mar. 31, 2019
Equity [Abstract]
STOCKHOLDERS' EQUITY	STOCKHOLDERS’ EQUITY Common Stock Offering On September 19, 2017, the Company closed an underwritten public offering of 24.1 million shares of its common stock, which included 3.1 million shares of common stock issued upon the exercise in full of the option to purchase additional shares granted to the underwriters in the offering. The shares were sold to the public at an offering price of $10.75 per share. The total net proceeds from the offering were $243.0 million, after underwriting discounts and commissions and offering expenses of approximately $15.7 million. The Company expects to continue to use the net proceeds from this offering to fund research and development efforts, including clinical trials for our proprietary candidates, build and scale its commercial capabilities, and for general working capital and corporate purposes. At-the-Market Equity Offering We entered into a sales agreement with Cantor Fitzgerald & Co. ("Cantor") dated March 27, 2013, which has been subsequently amended to permit Cantor, acting as our sales agent, to sell shares of our common stock from time to time in an at-the-market offering ("ATM Offering"). All sales of shares have been made pursuant to an effective shelf registration statement on Form S-3 filed with the SEC. On May 9, 2018, we entered into a subsequent sales agreement with Cantor (the "Sales Agreement"), pursuant to which we may, from time to time, sell up to $125.0 million in shares of our common stock through Cantor, acting as our sales agent and/or principal, in an ATM Offering. We were not required to sell shares under the Sales Agreement. We paid Cantor a commission of up to 3% of the aggregate gross proceeds we received from all sales of our common stock under the Sales Agreement. We received net proceeds on sales under the Sales Agreement of approximately $122.5 million at a weighted average price of $17.24 (excluding commissions) during the nine months ended March 31, 2019, which resulted in the full utilization of the $125.0 million available sales under the Sales Agreement. We received net proceeds on sales under our prior sales agreement with Cantor of approximately $40.3 million at a weighted average price of $16.14 during the nine months ended March 31, 2018. Effective May 7, 2019, we entered into a sales agreement with Jefferies LLC (the “Jefferies Sales Agreement”), pursuant to which we may, from time to time, sell up to $150.0 million in shares of our common stock through Jefferies LLC, acting as our sales agent and/or principal, in an at-the-market offering. We are not required to sell shares under the Jefferies Sales Agreement. We will pay Jefferies LLC a commission of up to 3% of the aggregate gross proceeds we receive from all sales of our common stock under the Jefferies Sales Agreement. Unless otherwise terminated, the Sales Agreement continues until the earlier of selling all shares available under the Jefferies Sales Agreement or May 7, 2022. No sales have been made under the Jefferies Sales Agreement.

STOCKHOLDERS’ EQUITY

Common Stock Offering

On September 19, 2017, the Company closed an underwritten public offering of 24.1 million shares of its common stock, which included 3.1 million shares of common stock issued upon the exercise in full of the option to purchase additional shares granted to the underwriters in the offering. The shares were sold to the public at an offering price of $10.75 per share. The total net proceeds from the offering were $243.0 million, after underwriting discounts and commissions and offering expenses of approximately $15.7 million. The Company expects to continue to use the net proceeds from this offering to fund research and development efforts, including clinical trials for our proprietary candidates, build and scale its commercial capabilities, and for general working capital and corporate purposes.

At-the-Market Equity Offering

We entered into a sales agreement with Cantor Fitzgerald & Co. ("Cantor") dated March 27, 2013, which has been subsequently amended to permit Cantor, acting as our sales agent, to sell shares of our common stock from time to time in an at-the-market offering ("ATM Offering"). All sales of shares have been made pursuant to an effective shelf registration statement on Form S-3 filed with the SEC.

On May 9, 2018, we entered into a subsequent sales agreement with Cantor (the "Sales Agreement"), pursuant to which we may, from time to time, sell up to $125.0 million in shares of our common stock through Cantor, acting as our sales agent and/or principal, in an ATM Offering. We were not required to sell shares under the Sales Agreement. We paid Cantor a commission of up to 3% of the aggregate gross proceeds we received from all sales of our common stock under the Sales Agreement. We received net proceeds on sales under the Sales Agreement of approximately $122.5 million at a weighted average price of $17.24 (excluding commissions) during the nine months ended March 31, 2019, which resulted in the full utilization of the $125.0 million available sales under the Sales Agreement. We received net proceeds on sales under our prior sales agreement with Cantor of approximately $40.3 million at a weighted average price of $16.14 during the nine months ended March 31, 2018.

Effective May 7, 2019, we entered into a sales agreement with Jefferies LLC (the “Jefferies Sales Agreement”), pursuant to which we may, from time to time, sell up to $150.0 million in shares of our common stock through Jefferies LLC, acting as our sales agent and/or principal, in an at-the-market offering. We are not required to sell shares under the Jefferies Sales Agreement. We will pay Jefferies LLC a commission of up to 3% of the aggregate gross proceeds we receive from all sales of our common stock under the Jefferies Sales Agreement. Unless otherwise terminated, the Sales Agreement continues until the earlier of selling all shares available under the Jefferies Sales Agreement or May 7, 2022. No sales have been made under the Jefferies Sales Agreement.